Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONALAAPG · Entity 4672 | SVP/General Counsel | March 18, 2026 | March 23, 2026 |
| OSIRIS THERAPEUTICS, INC.OSIR · Entity 158290 | Director | February 07, 2017 | February 09, 2018 |
| SELLAS Life Sciences Group, Inc.GALE · Entity 4313 | General Counsel | February 06, 2017 | February 07, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASCENTAGE PHARMA GROUP INTERNATIONAL
Report date March 18, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 362,444 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 362,444 |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2035-11-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. F1: The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
F2: The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
F3: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.
OSIRIS THERAPEUTICS, INC.
Report date February 07, 2017 · Filed February 09, 2018
This filing explicitly reported no securities owned.
SELLAS Life Sciences Group, Inc.
Report date February 06, 2017 · Filed February 07, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2027-02-06 | Direct | 10,000 |
Reported balance
After 2017-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-06 · Grant · Acquired 10,000 · Balance 10,000 F1: Granted pursuant to the Issuer's 2016 Incentive Plan. F2: This stock option will vest in equal, monthly installments over 8 months beginning May 1, 2017 through December 31, 2017, so long as the Reporting Person remains in the company's continuous employ through the vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Issuer's 2016 Incentive Plan.
F2: This stock option will vest in equal, monthly installments over 8 months beginning May 1, 2017 through December 31, 2017, so long as the Reporting Person remains in the company's continuous employ through the vesting period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2017 Filed Feb 7, 2017 16:58 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001394548-17-000011 · primary_doc.xml · derivative · entry 1 Knapp Thomas J · CIK 0001311726 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-06 F1 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F2 · derivative.exercise_date: This stock option will vest in equal, monthly installments over 8 months beginning May 1, 2017 through December 31, 2017, so long as the Reporting Person remains in the company's continuous employ through the vesting period. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:17 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001394548-17-000002 · primary_doc.xml · derivative · entry 1 Knapp Thomas J · CIK 0001311726 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 F1 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F2 · derivative.exercise_date: This stock option will vest in 16 equal, quarterly installments over four years beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period. Read SEC document |
| October 25, 2016 Filed Dec 20, 2016 17:12 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 102,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001394548-16-000004 · primary_doc.xml · derivative · entry 1 Knapp Thomas J · CIK 0001311726 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,000 Underlying: Common Stock · 102,000 shares Expires 2026-10-25 F1 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F2 · shares: The Reporting Person obtained the securities pursuant to an Employment Agreement Amendment dated October 1, 2016. The securities were convertible into common stock at the rate of 1 share of common stock for each 1 stock option share, or an aggregate of 102,000 shares of common stock (pre-reverse stock split). The securities were converted into 5,100 stock options at a price of $5.744 per share (post-reverse split) as of November 14, 2016. F3 · derivative.exercise_date: This stock option vests in equal monthly installments beginning November 25, 2016 and ending March 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.